<DOC>
	<DOCNO>NCT02768298</DOCNO>
	<brief_summary>The purpose study determine effect LCZ696 vs. Enalapril improvement excercise capacity patient chronic heart failure reduce ejection fraction</brief_summary>
	<brief_title>Exercise Capacity Study LCZ696 vs. Enalapril Patients With Chronic Heart Failure Reduced Ejection Fraction .</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Patients diagnosis chronic heart failure ( NYHA class III ) reduce ejection fraction ( LVEF ≤ 40 % ) Reduced ability exercise , evidence VO2peak ≤ 18 ml/min per kg Patients must ACEI ARB stable dose least enalapril 10 mg/d equivalent least 4 week study start History hypersensitivity allergy study drug , drug similar chemical class , ACEIs , ARBs , NEP inhibitor well know suspect contraindication study drug Previous history intolerance recommend target dos ACEIs ARBs Known history angioedema Requirement treatment ACEIs ARBs Current acute decompensated HF ( exacerbation chronic HF manifest sign symptom may require intravenous therapy ) Symptomatic hypotension impair renal function Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>systolic heart failure</keyword>
	<keyword>heart failure reduce ejection fraction</keyword>
	<keyword>exercise capacity</keyword>
</DOC>